ArticlePloS one2026
Novel peritoneal catheters with silver particles lower rates of peritonitis in patients with cirrhosis and refractory ascites.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment options for refractory ascites (RA) in cirrhosis are scarce. When TIPS insertion is contraindicated, tunneled peritoneal catheters (cPeCa) offer an alternative treatment. However, cPeCa are associated with high incidences of infection-related complications. Novel PeCa embedded with silver particles (sPeCa) have been introduced to address this issue.
methodsWe evaluated all patients with cirrhosis and RA treated with PeCa or ascites pump at Hannover Medical School from 2012-2023. Analysis was conducted utilizing a multivariable Competing-Risk-Analysis and afterwards a 3:1-Propensity-Score-Matching (PSM) to adjust for potential differences. Last, sPeCa-patients were compared to those with ascites pump. Study endpoints were mortality, peritonitis, device explantation and rehospitalization.
results150 patients with cPeCa were compared to 27 sPeCa-patients. Treatment with sPeCa was associated with significantly reduced incidences of peritonitis (HR 0.28, p = 0.002), device explantation (HR 0.37, p = 0.03) and rehospitalization (HR 0.48, p = 0.02). After PSM, 81 cPeCa-patients were compared to 27 sPeCa-patients. Mortality was comparable (HR 1.66, p = 0.29). Patients with sPeCa experienced less peritonitis (HR 0.34, p = 0.008), explantation (HR 0.39, p = 0.04) and rehospitalization (HR 0.52, p = 0.046). When compared to ascites-pump, sPeCa-patients demonstrated similar rates of mortality (HR 0.95, p = 0.94), peritonitis (HR 0.97, p = 0.96) and explantation (HR 0.89, p = 0.88), while rehospitalization rate was significantly higher in ascites pump (HR 2.83, p = 0.02).
conclusionTreatment with sPeCa is associated with less infection-associated complications and could therefore be a superior therapeutic approach compared to cPeCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.